standard-of-care treatment-Karolinska University Hospital-COVID-19

This refers to the specific standard-of-care (SOC) protocol used at Karolinska University Hospital for hospitalized patients with severe COVID-19 and respiratory distress during the ImmCoVA clinical trial (NCT04330638). The protocol includes oxygen supplementation to maintain SpO2 > 93%, thrombosis prophylaxis using low molecular weight heparins (such as dalteparin, tinzaparin, or enoxaparin) or direct oral anticoagulants (such as dabigatran, apixaban, or rivaroxaban), and corticosteroid therapy (specifically betamethasone 6 mg orally). This SOC served as the comparator arm against regimens supplemented with the interleukin inhibitors anakinra or tocilizumab.

Other names

SOCStandard-of-care treatment